Navigation Links
Ampio Pharmaceuticals Announces Agreement to Acquire Key Drug Delivery Technology
Date:12/5/2011

GREENWOOD VILLAGE, Colo., Dec. 5, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE—News) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced it has signed an agreement to acquire certain rights relating to a patented orally disintegrating tablet (ODT) drug delivery technology that can be used worldwide to elevate the market acceptance of Ampio's Zertane™ product for premature ejaculation. The Zertane™ ODT formulation allows for rapid oral absorption, ease of use without the need for liquids and avoids unpleasant bitter taste. This acquisition provides additional intellectual property to protect Zertane™ ODT's unique formulation, over and above the many method of use claims for Zertane™ contained in patents Ampio already owns.  The Company indicated that acquisition of the rights to this technology is expected to speed and facilitate Ampio's filing of marketing authorization applications for product regulatory approvals of Zertane™ worldwide and is important for the additional planned licensing and pricing agreements currently in negotiations.  The completion of the transaction is subject to customary conditions, including a certain third party consent and successful completion of a technology and materials transfer plan more fully described in a Form 8-K to be filed shortly.

"This acquisition of this technology is an important step in the manufacturing and commercialization plan for Zertane™. This agreement demonstrates our commitment to the fast and successful launch of a unique dosage and formulation of Zertane™. The Zertane™ commercialization plan is on course as outlined in the previous press releases and securities filings. We are committed to complete the development of a combination product of Zertane™ with a PDE5 inhibitor to simultaneously treat both premature ejaculation and erectile dysfunction. Our strategy with this line of products is to expeditiously pursue multiple licensing partners worldwide." stated Don Wingerter, Ampio's CEO.

About Ampio

Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease and male sexual dysfunction.  The product pipeline includes new uses of previously approved drugs and new molecular entities ("NMEs").  By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective, while their shorter development times can significantly increase near-term value.  A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs.  For more information about Ampio, please visit our website, www.ampiopharma.com.  

Forward-Looking Statements

Ampio's statements made in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions.  These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events.  The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Contact:

Investor Relations, Ampio Pharmaceuticals, Inc.  720-437-6500


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
2. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
3. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
4. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
5. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
6. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
7. Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
8. Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
9. Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
10. Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer
11. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Calif. , Jan. 20, 2017 ARMO ... 1b clinical data on the Company,s lead investigational immuno-oncology ... Symposium, co-sponsored by the American Society of Clinical Oncology ... San Francisco, CA. "AM0010 ... activated CD8 + T cells in the blood ...
(Date:1/21/2017)... -- Research and Markets has announced the addition of ... Route Of Administration, End User - Forecast to 2025" report ... ... a CAGR of around 7.8% over the next decade to reach ... analyzes the global markets for Advanced Drug Delivery across all the ...
(Date:1/20/2017)... Research and Markets has announced the addition of the ... Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic Panel, Liver Panel, Renal Panel, ... report to their offering. ... The global clinical laboratory testing market is expected to ... solutions on the grounds of maximum efficiency and minimum error is ...
Breaking Medicine Technology:
(Date:1/23/2017)... Los Angeles, California (PRWEB) , ... January 23, 2017 , ... ... “Golden Era” principles, has added Mr. Olympia Classic Physique bodybuilder Breon Ansley to its ... back began competing as a bodybuilder in 2012 and in less than a year ...
(Date:1/23/2017)... ... ... a story of love and redemption, hope and uncertainty as a girl makes her ... Inn at the Mill” is the creation of published author, Lois Kulp, who was born ... Berks County on Crow Hill. The inn, the mill and "Post Yokel" are ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Life Under Blankets”: an ... an early age. “Life Under Blankets” is the creation of published author, Kimberly Mitchell, ... Campus in Chicago. She went on to pursue a master’s degree in education in ...
(Date:1/22/2017)... ... January 22, 2017 , ... Phytocéane invites clients to take an exotic ... the world with ZANZIBAR MILKY CREAM. Inspired by the beauty of Zanzibar, a Tanzanian ... Oil and moisturizing vegetal coral to create this gentle, velvety body cream to envelop ...
(Date:1/22/2017)... ... January 22, 2017 , ... Medical lab testing through hospitals and ... a simple test will take days to arrive to the end customer, having to ... access to their lab tests, bypassing the cost and delay of traditional means. Now ...
Breaking Medicine News(10 mins):